208 related articles for article (PubMed ID: 24370352)
1. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
2. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.
Sofocleous CT; Violari EG; Sotirchos VS; Shady W; Gonen M; Pandit-Taskar N; Petre EN; Brody LA; Alago W; Do RK; D'Angelica MI; Osborne JR; Segal NH; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2015 Dec; 14(4):296-305. PubMed ID: 26277696
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
4.
Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer.
Cortesi E; Caponnetto S; Masi G; Urbano F; Mezi S; Gelibter A; Pelle G; Filippi L; Cianni R
Clin Colorectal Cancer; 2020 Dec; 19(4):e272-e276. PubMed ID: 32768271
[TBL] [Abstract][Full Text] [Related]
6. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
7. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT.
Garrean S; Muhs A; Bui JT; Blend MJ; Owens C; Helton WS; Espat NJ
World J Gastroenterol; 2007 Jun; 13(21):3016-9. PubMed ID: 17589957
[TBL] [Abstract][Full Text] [Related]
8. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
9. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.
Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M;
In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751
[TBL] [Abstract][Full Text] [Related]
10. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases.
Stubbs RS; Cannan RJ; Mitchell AW
J Gastrointest Surg; 2001; 5(3):294-302. PubMed ID: 11360053
[TBL] [Abstract][Full Text] [Related]
11. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Gibbs P; Do C; Lipton L; Cade DN; Tapner MJ; Price D; Bower GD; Dowling R; Lichtenstein M; van Hazel GA
BMC Cancer; 2015 Oct; 15():802. PubMed ID: 26503593
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
[TBL] [Abstract][Full Text] [Related]
14. Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres.
Badiyan S; Bhooshan N; Chuong MD; Sharma N; Akhter N; Etezadi V; Hausner P; Kudryasheva S; Kaiser A; Becker S; Guerrero M; Yi BY
Nucl Med Commun; 2018 Oct; 39(10):915-920. PubMed ID: 30124600
[TBL] [Abstract][Full Text] [Related]
15. Robust evidence for long-term survival with
Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
[TBL] [Abstract][Full Text] [Related]
16. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients.
Stubbs RS; O'Brien I; Correia MM
ANZ J Surg; 2006 Aug; 76(8):696-703. PubMed ID: 16916386
[TBL] [Abstract][Full Text] [Related]
17. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
Sharma RA; Van Hazel GA; Morgan B; Berry DP; Blanshard K; Price D; Bower G; Shannon JA; Gibbs P; Steward WP
J Clin Oncol; 2007 Mar; 25(9):1099-106. PubMed ID: 17369573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
